

Colorado HB 19-1131 Disclosure

LISRAYA™ (brepocitinib)

Priovant Therapeutics, Inc. ("Priovant") provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects the Priovant Wholesale Acquisition Cost ("WAC") for the Priovant product: **LISRAYA™**. The WAC represents the published catalogue or list price and may not represent actual transactional prices due to potential discounts, rebates, or other price concessions.

How much a patient will pay will depend on the patient's insurance coverage and available cost assistance programs.

WAC for LISRAYA™

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
LISRAYA™	87211-0030-30	Oral Tablet 30 MG	\$35,000

Generic versions of **LISRAYA™** include:

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Not applicable			

For more information on the price disclosure requirements, please contact the Colorado State Board of Pharmacy at:

State Board of Pharmacy
1560 Broadway, Suite 1350
Denver, CO 80202

Ph. (303) 894-7800 | Fax: (303) 894-7692 | Email: dora_pharmacyboard@state.co.us

LISRAYA™ is a trademark of Priovant Therapeutics, Inc.

Copyright© 2026 Priovant All rights reserved.

08/27/2026